Semaglutide
Also known as: Ozempic, Wegovy, Rybelsus
GLP-1 Receptor Agonist~4113.6 Da
An FDA-approved GLP-1 receptor agonist prescribed for type 2 diabetes management and chronic weight management in eligible patients.
Semaglutide is the most prominent peptide-based medication in clinical use today. As an FDA-approved glucagon-like peptide-1 (GLP-1) receptor agonist, it stands apart from research peptides by having undergone rigorous clinical trials involving tens of thousands of patients. Marketed under the brand names Ozempic, Wegovy, and Rybelsus, semaglutide has demonstrated significant efficacy for both type 2 diabetes management and chronic weight management. It is available only by prescription from licensed healthcare providers and represents the gold standard for what a thoroughly vetted, FDA-approved peptide medication looks like.
What Is Semaglutide?
Semaglutide is a synthetic analog of human glucagon-like peptide-1 (GLP-1), an incretin hormone naturally produced by L-cells in the intestine after eating. The native GLP-1 hormone has a half-life of only a few minutes because it is rapidly degraded by the enzyme dipeptidyl peptidase-4 (DPP-4). Semaglutide was engineered with structural modifications that make it resistant to DPP-4 degradation and allow it to bind to albumin in the blood, extending its half-life to approximately seven days. This allows for once-weekly dosing. Semaglutide has a molecular weight of approximately 4113.6 Da. It was developed by Novo Nordisk and first received FDA approval in 2017 for type 2 diabetes (Ozempic), followed by approvals for oral administration (Rybelsus, 2019) and chronic weight management (Wegovy, 2021).
How Semaglutide Has Been Studied
Semaglutide has the most extensive clinical research program of any peptide discussed on this site. The SUSTAIN clinical trial program for diabetes included multiple phase III trials enrolling thousands of patients, demonstrating significant reductions in HbA1c (a marker of long-term blood sugar control) compared to placebo and active comparators. The STEP clinical trial program for weight management demonstrated that patients receiving semaglutide 2.4 mg weekly achieved mean body weight reductions of approximately 15 percent from baseline over 68 weeks. The SELECT cardiovascular outcomes trial further demonstrated a 20 percent reduction in major adverse cardiovascular events in people with overweight or obesity and established cardiovascular disease. This level of clinical evidence is unmatched by any research peptide.
Proposed Mechanisms of Action
Semaglutide works through several well-characterized mechanisms. By binding to GLP-1 receptors on pancreatic beta cells, it enhances glucose-dependent insulin secretion, meaning it helps release insulin when blood sugar is elevated but has reduced effect when blood sugar is normal. It also suppresses glucagon secretion from alpha cells, reducing liver glucose output. In the gastrointestinal tract, semaglutide slows gastric emptying, which contributes to feeling full after smaller meals. Perhaps most significantly for weight management, semaglutide acts on GLP-1 receptors in the brain, particularly in the hypothalamus, to reduce appetite and food cravings. These central nervous system effects are considered the primary driver of the weight loss observed in clinical trials.
Common Goals Associated with Semaglutide
Semaglutide is primarily prescribed for two FDA-approved indications: type 2 diabetes management and chronic weight management in eligible adults. For diabetes, it helps achieve glycemic control and may reduce cardiovascular risk. For weight management, it is indicated for adults with a BMI of 30 or greater, or 27 or greater with at least one weight-related comorbidity such as hypertension, dyslipidemia, or cardiovascular disease. Some patients also seek semaglutide for metabolic health optimization more broadly, though prescribing outside of approved indications is at the provider discretion.
How Clinics Prescribe Semaglutide
Semaglutide is prescribed through both traditional medical practices and specialized clinics. For diabetes management, it is typically initiated and managed by endocrinologists or primary care physicians. For weight management, an increasing number of specialized weight loss clinics and telehealth platforms now offer semaglutide prescribing. The standard approach involves a gradual dose escalation over 16 to 20 weeks to minimize gastrointestinal side effects, starting at a low dose and increasing to the target therapeutic dose. Branded versions (Ozempic, Wegovy) are available through standard pharmacies. Some clinics also prescribe compounded semaglutide, though the FDA has raised concerns about compounded versions, particularly regarding purity and dosing accuracy.
Safety and Regulatory Status
As an FDA-approved medication, semaglutide has undergone extensive safety evaluation. Common side effects include nausea, vomiting, diarrhea, and constipation, which are most prominent during dose escalation and tend to diminish over time. Semaglutide carries a boxed warning regarding thyroid C-cell tumors observed in rodent studies, and it is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Other safety considerations include potential risk of pancreatitis, gallbladder disease, and hypoglycemia when used with insulin or sulfonylureas. The drug has been studied in large populations with long-term follow-up, providing a level of safety data unavailable for research peptides. Insurance coverage varies by indication and plan.
Comparison with Related Peptides
Semaglutide occupies a unique position in the peptide landscape as the only compound discussed on this site with full FDA approval and extensive phase III clinical trial data. Other GLP-1 receptor agonists include tirzepatide (a dual GIP/GLP-1 agonist) and liraglutide, which have different pharmacokinetic profiles and clinical applications. Semaglutide should not be confused with growth hormone secretagogues like ipamorelin and CJC-1295, which work through entirely different hormonal pathways targeting growth hormone release rather than metabolic regulation. Tissue repair peptides like BPC-157 and TB-500 are also unrelated in mechanism and indication. The comparison is relevant because it highlights the spectrum from fully approved medications with robust evidence to research compounds with preliminary data, helping patients calibrate their expectations and risk assessments accordingly.
Related Goals
Compare Related Peptides
BPC-157
A synthetic pentadecapeptide derived from a protective protein found in human gastric juice, investigated in preclinical research for tissue repair and gastrointestinal protection.
CJC-1295
A synthetic analog of growth hormone-releasing hormone (GHRH) designed for sustained growth hormone elevation through extended half-life.
Ipamorelin
A selective growth hormone secretagogue peptide studied for its ability to stimulate growth hormone release with fewer side effects compared to earlier secretagogues.
TB-500
A synthetic peptide fragment of thymosin beta-4, a naturally occurring protein involved in cell migration and tissue repair, studied primarily in preclinical research.
Find Peptide Clinics Near You
Peptide Clinics in Austin — Directory & Guide
Find peptide therapy clinics in Austin, TX. Compare providers, learn about treatments, and understand what to look for in an Austin peptide clinic.
Peptide Clinics in Los Angeles — Directory & Guide
Find peptide therapy clinics in Los Angeles. Compare providers, learn about treatments, and understand what to look for in an LA peptide clinic.
Peptide Clinics in Miami — Directory & Guide
Find peptide therapy clinics in Miami, FL. Compare providers, learn about available treatments, and understand what to look for in a Miami peptide clinic.
Peptide Clinics in New York — Directory & Guide
Find peptide therapy clinics in New York City. Compare providers, learn about treatments, and understand what to look for in a NYC peptide clinic.
Peptide Clinics in Scottsdale — Directory & Guide
Find peptide therapy clinics in Scottsdale, AZ. Compare providers, learn about treatments, and understand what to look for in a Scottsdale peptide clinic.
Further Reading
How to Evaluate a Peptide Clinic — A Patient's Checklist
Learn how to evaluate peptide therapy clinics. Understand what credentials to look for, red flags to avoid, and questions to ask before starting treatment.
Peptide Legality in the United States — What You Need to Know
Understand the legal status of peptides in the United States, including FDA regulations, compounding pharmacy rules, and state-level considerations.
Peptide Therapy Explained — How It Works
Understand how peptide therapy works, what to expect from treatment, and how to evaluate whether peptide therapy may be appropriate for you.
Research Peptides vs. Prescription Peptides — Key Differences
Understand the critical differences between research peptides and prescription peptides, including safety, legality, and quality considerations.
What Are Peptides? A Beginner's Guide
Learn what peptides are, how they work in the body, and why they are gaining attention in medical research and clinical practice.
Frequently Asked Questions
Is semaglutide a peptide?
What is the difference between Ozempic, Wegovy, and Rybelsus?
Do you need a prescription for semaglutide?
What are the common side effects of semaglutide?
How much weight can you lose on semaglutide?
Last reviewed: 3/14/2026